Principal Scientist, Formulation

Burlington, United States


Posted on: October 8, 2020

Closing: November 07, 2020

Salary: Undisclosed

Position Type: Full Time

Job Description

How will you make an impact?

The Principal Formulation Scientist, based in Burlington, Massachusetts, will be responsible for leading the formulation development and testing efforts within our ocular drug development programs. Located at our labs in Burlington, MA and interfacing with cross functional team members from our Waltham, MA and San Clemente CA offices, you will join a growing dynamic team of interdisciplinary scientists on the forefront of pharmaceutical therapies for glaucoma, corneal health, and retinal diseases.

What will you do?

·         Be the lead innovator involved in the groundbreaking development of novel formulations for multiple new drug entities and indications.

·         Contribute at the bench and intellectually to evaluate and deliver fit-for-purpose GLP Tox and FIH ocular formulations.

·         Coordinate CRO and consultant activities for drug product in vivo studies.

·         Prepare protocols and project reports for preclinical CMC studies and interactions with regulatory authorities.

·         Manage junior scientists in goal setting and career development.

·         Bring on new technologies and instrumentation to improve efficiencies and develop new IP.

How will you get here?


·         A PhD in pharmacology/biochemistry/biophysics with a minimum of 5+ years industrial experience, or MS with 10+ years’ experience.


·         A demonstrated ability to develop novel, high-quality, ocular formulations necessary for both pre-clinical and clinical evaluation of small molecule therapeutics.

·         Expert knowledge of assay techniques and instrumentation necessary for the evaluation of API’s and drug product liquid dosage forms (UPLC/MS, viscosity, osmolarity, dissolution, DSC, TGA).

·         Experience with management of CROs, external resources and collaborators.

·         Expert knowledge with regulatory and quality systems (SOPs, QA/QC, GLP, GMP), protocol and report preparation and review.

·         Superior oral and written communication skills with excellent working knowledge of MS Office tools, statistical analysis, and relevant scientific software.

·         Be self-motivated, well organized, and highly effective in a cross-functional team-oriented environment.

·         Extensive experience within the ocular therapeutics field.

·         Experience with topical drug delivery to the cornea is highly desirable.

·         Direct experience with goal setting and management of junior staff scientists.

Glaukos Corporation is an Equal Opportunity/Affirmative Action Employer. All qualified applicants will receive consideration for employment without regard to race, color, religion, sex including sexual orientation and gender identity, national origin, disability, protected Veteran Status, or any other characteristic protected by applicable federal, state, or local law.



Glaukos Corporation is an ophthalmic medical technology and pharmaceutical company focused on the development and commercialization of novel surgical devices and sustained pharmaceutical therapies designed to transform the treatment of glaucoma, one of the world’s leading causes of blindness.

The company pioneered Micro-Invasive Glaucoma Surgery, or MIGS, in order to revolutionize the traditional glaucoma treatment and management paradigm. Glaukos launched the iStent®, its first MIGS device, in the United States in 2012 and is leveraging its platform technology to build a comprehensive and proprietary portfolio of micro-scale injectable therapies designed to address the complete range of glaucoma disease states and progression.

The company’s second-generation MIGS device, the iStent inject® Trabecular Micro-Bypass System, was approved by the Food and Drug Administration, or FDA in June 2018. The company believes the iStent inject,® measuring 0.23 mm wide and 0.36 mm long, is the smallest medical device ever approved by the FDA.

In June 2015, Glaukos completed an initial public offering and our shares are now traded on the New York Stock Exchange under the ticker symbol “GKOS”. The company was founded in 1998 and is based in San Clemente, California.


Posted on: October 8, 2020

Closing: November 07, 2020

Salary($): Undisclosed

Position Type: Full Time

To view the entire job posting or to apply for this position, join the Xtalks community for free. Advance your career, get access to industry webinars, articles, videos, and more.